Array Biopharma (NASDAQ: ARRY) reported Q3 EPS of ($0.17), $0.03 better than the analyst estimate of ($0.20). Revenue for the quarter came in at $64.7 million versus the consensus estimate of $54.04 million.

For earnings history and earnings-related data on Array Biopharma (ARRY) click here.